DE3585061D1 - Verwendung eines spezifischen tumorassoziierten antigens, sialosyllactotetraose, in diagnose- oder therapieverfahren bezueglich krebskrankheiten. - Google Patents

Verwendung eines spezifischen tumorassoziierten antigens, sialosyllactotetraose, in diagnose- oder therapieverfahren bezueglich krebskrankheiten.

Info

Publication number
DE3585061D1
DE3585061D1 DE8585850256T DE3585061T DE3585061D1 DE 3585061 D1 DE3585061 D1 DE 3585061D1 DE 8585850256 T DE8585850256 T DE 8585850256T DE 3585061 T DE3585061 T DE 3585061T DE 3585061 D1 DE3585061 D1 DE 3585061D1
Authority
DE
Germany
Prior art keywords
lactotetraose
antigent
sialosyl
diagnosis
tumor associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8585850256T
Other languages
English (en)
Inventor
Jan Roland Holmgren
Leif Gustav Lindholm
Lars Torvald Svennerholm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Kabi Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia AB filed Critical Kabi Pharmacia AB
Application granted granted Critical
Publication of DE3585061D1 publication Critical patent/DE3585061D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE8585850256T 1984-08-28 1985-08-06 Verwendung eines spezifischen tumorassoziierten antigens, sialosyllactotetraose, in diagnose- oder therapieverfahren bezueglich krebskrankheiten. Expired - Lifetime DE3585061D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8404283A SE455445B (sv) 1984-08-28 1984-08-28 Antikroppar mot sialosyllaktotetraos (iv?723neuaclcose?714) och antikroppens resp antigenets anvendning vid tumordiagnostik

Publications (1)

Publication Number Publication Date
DE3585061D1 true DE3585061D1 (de) 1992-02-13

Family

ID=20356831

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585850256T Expired - Lifetime DE3585061D1 (de) 1984-08-28 1985-08-06 Verwendung eines spezifischen tumorassoziierten antigens, sialosyllactotetraose, in diagnose- oder therapieverfahren bezueglich krebskrankheiten.

Country Status (5)

Country Link
EP (1) EP0173663B1 (de)
JP (1) JPH0690204B2 (de)
AT (1) ATE71225T1 (de)
DE (1) DE3585061D1 (de)
SE (1) SE455445B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0287916A1 (de) * 1987-04-13 1988-10-26 Otsuka Pharmaceutical Co., Ltd. Immunoassay
US5079353A (en) * 1987-12-02 1992-01-07 Chembiomed, Ltd. Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
EP0380084A3 (de) * 1989-01-27 1991-03-13 The Biomembrane Institute Methode zur Hemmung dvon Zell-Zell- und Zellsubstrat-Wechselwirkungen durch Blockierung der Kohlenhydrat-Kohlenhydrat-Wechselwirkungen
AU5178090A (en) * 1989-03-09 1990-10-09 Sendai Institute of Microbiology, The Monoclonal antibody, and assay method, reagent kit, search method and drug missile using said antibody
CA2432978C (en) 2000-12-22 2012-08-28 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
US9217749B2 (en) 2006-05-31 2015-12-22 Lpath, Inc. Immune-derived moieties reactive against lysophosphatidic acid
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US8796429B2 (en) 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
US8444970B2 (en) 2006-10-27 2013-05-21 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
MX2009004532A (es) 2006-10-27 2009-09-04 Lpath Inc Composiciones y metodos para unir esfingosina-1-fosfato.
US8361465B2 (en) 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4471057A (en) * 1981-06-30 1984-09-11 The Wistar Institute Detection of colorectal carcinoma
ATE56046T1 (de) * 1983-03-04 1990-09-15 Health Research Inc Monoklonale antikoerper gegen humane brustkarzinomzellen und ihre verwendung in der diagnose und therapie.
US4569788A (en) * 1983-05-18 1986-02-11 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies against non small cell lung cancer

Also Published As

Publication number Publication date
SE8404283D0 (sv) 1984-08-28
EP0173663B1 (de) 1992-01-02
SE455445B (sv) 1988-07-11
SE8404283L (sv) 1986-03-01
JPS61116660A (ja) 1986-06-04
JPH0690204B2 (ja) 1994-11-14
ATE71225T1 (de) 1992-01-15
EP0173663A3 (en) 1987-10-07
EP0173663A2 (de) 1986-03-05

Similar Documents

Publication Publication Date Title
NZ210867A (en) Tumour-specific monoclonal antibodies, production thereof and use
DE3585061D1 (de) Verwendung eines spezifischen tumorassoziierten antigens, sialosyllactotetraose, in diagnose- oder therapieverfahren bezueglich krebskrankheiten.
IT8419266A1 (it) Dispositivo per generare calore in tessuti" del corpo umano e procedimento di cenerazione di calore, particolarmente per la cura di tumori
DK2289D0 (da) Monoklonale antistoffer samt deres fremstilling og anvendelse
EP0674661A4 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis.
EP0232871A3 (de) Menschlicher monoklonaler Antikörper, Hybridoma zu seiner Herstellung und seine Verwendung
GB2182949A (en) Monoclonal antibodies and antigens for human non-small cell lung carcinomas
ATE216266T1 (de) Einen liganden enthaltendes arzneimittel zur behandlung und/oder diagnose von weichgeweben- tumoren
ATE64531T1 (de) Tumortherapeutikum und verfahren zu seiner herstellung.
ES2012997A6 (es) Un procedimiento para la obtencion de una linea de celulas hibridas que producen un anticuerpo monoclonal.
DE3582191D1 (de) Verwendung eines spezifischen karzinomassoziierenden antigens (hapten), fucosylsialosylgangliotetrose (fuc-gm1) in diagnostischen und therapeutischen verfahren betreffend den menschlichen lungenkrebs (carcinomas von kleinen zellen).
EP0280135A3 (en) Protein c-inhibitor (pci) as a pharmaceutical and diagnostic agent, process for the preparation of such a pharmaceutical or diagnostic agent and a composition containing pci
EP0232706A3 (de) Blutgruppe-Antigen-Platte
ES2121881T3 (es) Anticuerpos monoclonales anti-gangliosidos, su preparacion y su empleo como agente terapeutico de tumores.
ATE84069T1 (de) Murin-hybridoma lym-2 und diagnostikantikoerper, der dadurch hergestellt ist.
Cangelosl et al. A creative approach to pediatric radiation oncology: A chiia'b eye view of radiation therapy and an activity book
NO883040L (no) Middel for undersoekelse av tumorer, samt fremgangsmaate for fremstilling av et slikt middel.
MC1518A1 (fr) Procede de diagnostic et de traitement therapeutique de tumeurs et/ou de maladies infectieuses de natures diverses au moyen de preparations de composes d'alcaloides ou de leurs sels
IT8819818A0 (it) Metodo per il controllo quantitativo del mutamento di posizione o il riposizionamento di pazienti nel rilievo di immagini radiografiche e/o in terapie per irraggiamento.
ATE95426T1 (de) Humanes karcinom-assoziertes antigen und an dieses antigen bindende antikoerper.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition